Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.

Kale V, List AF

DOI: 10.2174/138920106778521587
Published: 2006 Oct
Container: Current pharmaceutical biotechnology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2174/138920106778521587,
  title = {Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.},
  author = {Kale V and List AF},
  year = {2006},
  journal = {Current pharmaceutical biotechnology},
  doi = {10.2174/138920106778521587},
  url = {https://doi.org/10.2174/138920106778521587}
}

RIS

TY  - JOUR
TI  - Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.
AU  - Kale V
AU  - List AF
PY  - 2006
JO  - Current pharmaceutical biotechnology
DO  - 10.2174/138920106778521587
UR  - https://doi.org/10.2174/138920106778521587
ER  -

APA

V, K., & AF, L. (2006). Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.. Current pharmaceutical biotechnology. https://doi.org/10.2174/138920106778521587

Source records

pubmed · retrieved 2026-09-25T05:48:49.372Z
europe-pmc · retrieved 2026-09-25T05:48:49.392Z